9X COVID-19 survival in nursing home if had 80,000 IU dose of vitamin D in previous month – Oct 2020
Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study
Nutrients 2020, 12(11), 3377; https://doi.org/10.3390/nu12113377
by Gaëlle Annweiler 1,2, Mathieu Corvaisier 3,4, Jennifer Gautier 3, Vincent Dubée 1,5,6, Erick Legrand 1,7, Guillaume Sacco 3,8 and Cédric Annweiler 1,3,8,9,10,* on behalf of the GERIA-COVID study group
Chart of data by VitaminDWiki
Review of Study by Grassroots Health
Background. The objective of this quasi-experimental study was to determine whether bolus vitamin D supplementation taken either regularly over the preceding year or after the diagnosis of COVID-19 was effective in improving survival among hospitalized frail elderly COVID-19 patients.
Methods. Seventy-seven patients consecutively hospitalized for COVID-19 in a geriatric unit were included. Intervention groups were participants regularly supplemented with vitamin D over the preceding year (Group 1), and those supplemented with vitamin D after COVID-19 diagnosis (Group 2). The comparator group involved participants having received no vitamin D supplements (Group 3). Outcomes were 14-day mortality and highest (worst) score on the ordinal scale for clinical improvement (OSCI) measured during COVID-19 acute phase. Potential confounders were age, gender, functional abilities, undernutrition, cancer, hypertension, cardiomyopathy, glycated hemoglobin, number of acute health issues at admission, hospital use of antibiotics, corticosteroids, and pharmacological treatments of respiratory disorders.
Results. The three groups (n = 77; mean ± SD, 88 ± 5years; 49% women) were similar at baseline (except for woman proportion, p = 0.02), as were the treatments used for COVID-19. In Group 1 (n = 29), 93.1% of COVID-19 participants survived at day 14, compared to 81.2% survivors in Group 2 (n = 16) (p = 0.33) and 68.7% survivors in Group 3 (n = 32) (p = 0.02). While considering Group 3 as reference (hazard ratio (HR) = 1), the fully-adjusted HR for 14-day mortality was HR = 0.07 (p = 0.017) for Group 1 and HR = 0.37 (p = 0.28) for Group 2. Group 1 had longer survival time than Group 3 (log-rank p = 0.015), although there was no difference between Groups 2 and 3 (log-rank p = 0.32). Group 1, but not Group 2 (p = 0.40), was associated with lower risk of OSCI score ≥5 compared to Group 3 (odds ratio = 0.08, p= 0.03).
Conclusions. Regular bolus vitamin D supplementation was associated with less severe COVID-19 and better survival in frail elderly.
Download the PDF from VitaminDWiki
COVID-19 treated by Vitamin D - studies, reports, videos in VitaminDWiki
As of April 12 the page had: 34 trials, 5 trial results, 17 meta-analyses and reviews, 52 observations, 34 recommendations, 54 associations, 86 speculations, 43 videos see related: Governments, HealthProblems, Hospitals, Dark Skins, 26 risk factors are ALL associated with low Vit D, Recent Virus pages Fight COVID-19 with 50K Vit D weekly
Items in both categories Virus and Loading Dose are listed here:
- Infectious Mononucleosis (virus) treated by high dose Vitamin D (3 cases) – March 2021
- Vitamin D reduced COVID-19 inflammation (60,000 IU daily for 8 days) - RCT Feb 2021
- Those getting intermittent vitamin D were 7 X less likely to die of COVID-19 - Dec 11, 2020
- COVID-19 Vitamin D: Overview by Dr. in Sri Lanka (Video and transcript) - Dec 8, 2020
- Vitamin D has eliminated ICU COVID-19 in hospital in Dubai since June - Sept 26, 2020
- Severe COVID-19 not fought by vitamin D when given too late - RCT Nov 18, 2020
- COVID-19 defeated 3x faster by 420,000 IU Vitamin D nanoemulsion – RCT Nov 12, 2020
- French National Academy recommended 100,000 IU of Vitamin D to elderly to fight COVID-19 - May 2020
- Residents of a Nursing Home who choose monthly Vitamin D had 4X fewer COVID-19 deaths – Nov 2, 2020
- Cerebral malaria deaths prevented by loading dose of vitamin D (mice) – Sept 2018
Note: The highlighted author of this paper is the Principal Investigator for Clinical Trial #5
There have actually been
|1080 visitors, last modified 15 Dec, 2020,